medicalmarketnews.com
Novartis' $90 Million Swiss Plant to Solve Cell Therapy Bottleneck - Medical Market News
Swiss drug producer, Novartis’s new $90 million cell and gene therapy plant in northern Switzerland, is on track to start commercial production of its cell therapy Kymriah for cancer next year. The new plant, anticipated to employ 450 people, will enable the drugmaker to make its Kymriah therapy for European patients without first having to …